Ivermectin, a potential anticancer drug derived from an antiparasitic drug
https://pubmed.ncbi.nlm.nih.gov/32971268/
Mingyang Tang 1, Xiaodong Hu 2, Yi Wang 3, Xin Yao 4, Wei Zhang 5, Chenying Yu 6, Fuying Cheng 7, Jiangyan Li 8, Qiang Fang 9
Affiliations expand
PMID: 32971268 PMCID: PMC7505114 DOI: 10.1016/j.phrs.2020.105207
Free PMC article
Abstract
Ivermectin is a macrolide antiparasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi ōmura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the excellent efficacy of ivermectin against parasitic diseases. Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways. This suggests that ivermectin may be an anticancer drug with great potential. Here, we reviewed the related mechanisms by which ivermectin inhibited the development of different cancers and promoted programmed cell death and discussed the prospects for the clinical application of ivermectin as an anticancer drug for neoplasm therapy.
Keywords: avermectin(PubChem CID：6434889); cancer; doramectin(PubChem CID：9832750); drug repositioning; ivermectin; ivermectin(PubChem CID：6321424); moxidectin(PubChem CID：9832912); selamectin(PubChem CID：9578507).
Copyright © 2020 Elsevier Ltd. All rights reserved.
Thanks. Going down the Ivermectin / cancer rabbit hole is on my to-do list for 2022.
Amazing therapeutic. Truly amazing. Thanks for posting.
Now folks will (hopefully) understand, even more, why TPTB were/are so adamant about the withholding of this drug.
Criminal.